Patents Assigned to Biomedica Management Corporation
-
Publication number: 20150359857Abstract: ClotSpray is a sprayable fibrin-based hemostatic agent applied from an aerosol can. The agent is intended for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and treatment of burns. It can be applied topically to the wound from an aerosol can without need of preparation, unfreezing or interruption during the length of the surgical procedure. Its crosslinking technology generates an adhesive fibrin sealant required for hemostasis. The attachment properties of the gel as well as the instant formation of a fibrin gel ensures that a strong stable fibrin clot will control light to moderate bleeding from a wound.Type: ApplicationFiled: April 7, 2014Publication date: December 17, 2015Applicant: Biomedica Management CorporationInventors: George David Falus, Leonid Medved
-
Patent number: 8367802Abstract: A hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, it produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The fibrin components are produced by a novel dialysis method which does not present thrombin to the immune system and can be maintained in solution for six weeks without significant proteolytic degradation.Type: GrantFiled: June 18, 2009Date of Patent: February 5, 2013Assignee: Biomedica Management CorporationInventors: George David Falus, Leonid Medved
-
Publication number: 20120142621Abstract: A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola. The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then decanted as a dense oil from the culture broth, subsequently washed to remove free fatty acids. Secondary chemical transformation via base catalyzed hydrolysis is used to reduce the 8 possible structural sophorolipid species to a single moiety, the 17-L-[(2?-O-b-D-glucopyranosyl-b-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de-acetylated free acid. The compound acts primarily through decreasing inflammatory cytokines and eliciting other synergistic anti-inflammatory mechanisms by blocking TLR4-CD14 upstream of the inflammatory signaling cascade.Type: ApplicationFiled: August 2, 2011Publication date: June 7, 2012Applicant: Biomedica Management CorporationInventors: George Falus, Maja Nowakowski, Martin Bluth, John Aikens
-
Publication number: 20100256671Abstract: ClotFoam is an hemostatic agent designed for non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .Type: ApplicationFiled: April 7, 2009Publication date: October 7, 2010Applicant: BIOMEDICA MANAGEMENT CORPORATIONInventor: George Falus
-
Publication number: 20100197893Abstract: ClotFoam is an hemostatic agent designed for use in cases of non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue.Type: ApplicationFiled: June 18, 2009Publication date: August 5, 2010Applicant: BIOMEDICA MANAGEMENT CORPORATIONInventors: George Falus, Leonid Medved